← Grant listing · GrantsDue Pro

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)

National Institutes of Health · PAR-25-299 · Deadline: January 7, 2028

Program-level history — this opportunity doesn't publish per-opportunity awards, so these numbers describe its parent program (CFDA 93.273, Alcohol Research Programs), not this competition alone. Labeled that way on purpose.

Draw-down reality (program)

Across 84 completed awards in this program (FY2021+ sample, USAspending outlay records), grantees ultimately drew a median 96% of obligated funds. A median well under 100% means underspend or early closure is common here — worth knowing before promising a spend-down timeline.

Listing summary

This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.). This NOFO is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025.

Eligibility: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations (other), Nonprofits with 501(c)(3), other than higher education, Nonprofits without 501(c)(3), Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others · Categories: Education, Health · official listing ↗

Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.